GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longevity Biomedical Inc (NAS:LBIO) » Definitions » Asset Turnover

Longevity Biomedical (Longevity Biomedical) Asset Turnover : 0.00 (As of . 20)


View and export this data going back to 2050. Start your Free Trial

What is Longevity Biomedical Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Longevity Biomedical's Revenue for the six months ended in . 20 was $ Mil. Longevity Biomedical's Total Assets for the quarter that ended in . 20 was $ Mil. Therefore, Longevity Biomedical's Asset Turnover for the quarter that ended in . 20 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Longevity Biomedical's annualized ROE % for the quarter that ended in . 20 was %. It is also linked to ROA % through Du Pont Formula. Longevity Biomedical's annualized ROA % for the quarter that ended in . 20 was %.


Longevity Biomedical Asset Turnover Historical Data

The historical data trend for Longevity Biomedical's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longevity Biomedical Asset Turnover Chart

Longevity Biomedical Annual Data
Trend
Asset Turnover

Longevity Biomedical Semi-Annual Data
Asset Turnover

Competitive Comparison of Longevity Biomedical's Asset Turnover

For the Biotechnology subindustry, Longevity Biomedical's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Longevity Biomedical's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longevity Biomedical's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Longevity Biomedical's Asset Turnover falls into.



Longevity Biomedical Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Longevity Biomedical's Asset Turnover for the fiscal year that ended in . 20 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: . 20 )/( (Total Assets (A: . 20 )+Total Assets (A: . 20 ))/ count )
=/( (+)/ )
=/
=

Longevity Biomedical's Asset Turnover for the quarter that ended in . 20 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: . 20 )/( (Total Assets (Q: . 20 )+Total Assets (Q: . 20 ))/ count )
=/( (+)/ )
=/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Longevity Biomedical  (NAS:LBIO) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Longevity Biomedical's annulized ROE % for the quarter that ended in . 20 is

ROE %**(Q: . 20 )
=Net Income/Total Stockholders Equity
=/
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=( / )*( / )*(/ )
=Net Margin %*Asset Turnover*Equity Multiplier
= %**
=ROA %*Equity Multiplier
= %*
= %

Note: The Net Income data used here is two times the semi-annual (. 20) net income data. The Revenue data used here is two times the semi-annual (. 20) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Longevity Biomedical's annulized ROA % for the quarter that ended in . 20 is

Note: The Net Income data used here is two times the semi-annual (. 20) net income data. The Revenue data used here is two times the semi-annual (. 20) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Longevity Biomedical Asset Turnover Related Terms

Thank you for viewing the detailed overview of Longevity Biomedical's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Longevity Biomedical (Longevity Biomedical) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
12100 NE 195th street, Suite 150, Bothell, WA, USA, 98011
Longevity Biomedical Inc is a clinical-stage biomedical company. The company is focused on the advancement of new technologies across therapeutics, monitoring, and digital health that aim to restore tissue form and function to increase health span. Longevity is acquiring a differentiated therapeutic pipeline of late-stage clinical technologies across ophthalmology, cardiovascular disease, and soft tissue reconstruction and repair.

Longevity Biomedical (Longevity Biomedical) Headlines

No Headlines